James B Wetmore1, Konstantin Gurevich2, Stuart Sprague3, Gerald Da Roza4, John Buerkert5, Maureen Reiner6, William Goodman6, Kerry Cooper6. 1. Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota; james.wetmore@hcmed.org. 2. Fresenius Medical Care, St. Petersburg, Russia; 3. Division of Nephrology and Hypertension, NorthShore University HealthSystem, Evanston, Illinois; 4. Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 5. Columbia Nephrology Associates, Columbia, South Carolina; and. 6. Amgen Inc., Thousand Oaks, California.
Abstract
BACKGROUND AND OBJECTIVES: Direct comparison of cinacalcet and vitamin D analogs as monotherapies to lower parathyroid hormone (PTH) levels has not been undertaken. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective, multicenter, phase 4, randomized, open-label study that enrolled participants from 2010 to 2012. Adult participants (n=312) on hemodialysis with PTH >450 pg/ml were randomized 1:1 to 12 months of treatment with either cinacalcet (n=155) or vitamin D analogs (n=157) to evaluate the mean percentage change in plasma PTH level (primary end point) and the proportion of participants achieving plasma PTH <300 pg/ml or a ≥30% decrease in PTH (secondary end points). A preplanned analysis to determine whether there were important region-by-treatment interactions was also undertaken. RESULTS: Baseline mean PTH was 846 pg/ml (n=155) for cinacalcet and 816 pg/ml (n=157) for vitamin D analog therapy. The mean (95% confidence interval) percentage change from baseline in PTH was -12.1% (-20.0% to -4.1%) in the cinacalcet arm and -7.0% (-14.9% to 0.8%) in the vitamin D analog arm, a difference of -5.0% (-15.4% to 5.4%) (P=0.35). Similarly, there was no difference in achievement of secondary efficacy end points between arms (19.4% and 15.3% of participants with PTH≤300 pg/ml and 42.6% and 33.8% of participants had a PTH reduction >30% in the cinacalcet and vitamin D analog arms, respectively). A prespecified analysis revealed a large treatment-by-region interaction, with nominally greater response to cinacalcet compared with vitamin D analogs in non-United States participants (US versus non-US participants, P<0.001). Hypocalcemia was more common in the cinacalcet arm, whereas hypercalcemia and hyperphosphatemia occurred more often in the vitamin D analog arm. CONCLUSIONS: Participants had similar modest reductions in PTH with either cinacalcet or vitamin Danalog monotherapy over 52 weeks of treatment, but effects varied by region. Treatments differed with regard to effect on calcium and phosphorus levels.
RCT Entities:
BACKGROUND AND OBJECTIVES: Direct comparison of cinacalcet and vitamin D analogs as monotherapies to lower parathyroid hormone (PTH) levels has not been undertaken. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective, multicenter, phase 4, randomized, open-label study that enrolled participants from 2010 to 2012. Adult participants (n=312) on hemodialysis with PTH >450 pg/ml were randomized 1:1 to 12 months of treatment with either cinacalcet (n=155) or vitamin D analogs (n=157) to evaluate the mean percentage change in plasma PTH level (primary end point) and the proportion of participants achieving plasma PTH <300 pg/ml or a ≥30% decrease in PTH (secondary end points). A preplanned analysis to determine whether there were important region-by-treatment interactions was also undertaken. RESULTS: Baseline mean PTH was 846 pg/ml (n=155) for cinacalcet and 816 pg/ml (n=157) for vitamin D analog therapy. The mean (95% confidence interval) percentage change from baseline in PTH was -12.1% (-20.0% to -4.1%) in the cinacalcet arm and -7.0% (-14.9% to 0.8%) in the vitamin D analog arm, a difference of -5.0% (-15.4% to 5.4%) (P=0.35). Similarly, there was no difference in achievement of secondary efficacy end points between arms (19.4% and 15.3% of participants with PTH≤300 pg/ml and 42.6% and 33.8% of participants had a PTH reduction >30% in the cinacalcet and vitamin D analog arms, respectively). A prespecified analysis revealed a large treatment-by-region interaction, with nominally greater response to cinacalcet compared with vitamin D analogs in non-United States participants (US versus non-US participants, P<0.001). Hypocalcemia was more common in the cinacalcet arm, whereas hypercalcemia and hyperphosphatemia occurred more often in the vitamin D analog arm. CONCLUSIONS:Participants had similar modest reductions in PTH with either cinacalcet or vitamin D analog monotherapy over 52 weeks of treatment, but effects varied by region. Treatments differed with regard to effect on calcium and phosphorus levels.
Authors: Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Pablo Ureña-Torres; Ian Bridges; Cynthia Christiano; Serge H Cournoyer; Kerry Cooper; Mourad Farouk; Nelson P Kopyt; Mariano Rodriguez; Daniel Zehnder; Adrian Covic Journal: Nephrol Dial Transplant Date: 2013-01-16 Impact factor: 5.992
Authors: Sharon M Moe; Glenn M Chertow; Jack W Coburn; L Darryl Quarles; William G Goodman; Geoffrey A Block; Tilman B Drüeke; John Cunningham; Donald J Sherrard; Laura C McCary; Kurt A Olson; Stewart A Turner; Kevin J Martin Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Pablo Ureña; Stefan H Jacobson; Emanuel Zitt; Marc Vervloet; Fabio Malberti; Neil Ashman; Sean Leavey; Marianne Rix; Ingrid Os; Heikki Saha; Miroslav Ryba; Veronika Bencova; Ana Baños; Valter Zani; Denis Fouque Journal: Nephrol Dial Transplant Date: 2009-04-15 Impact factor: 5.992
Authors: Geoffrey A Block; Steven Zeig; Jared Sugihara; Glenn M Chertow; Eric M Chi; Stewart A Turner; David A Bushinsky Journal: Nephrol Dial Transplant Date: 2008-02-29 Impact factor: 5.992
Authors: Markus Ketteler; Kevin J Martin; Myles Wolf; Michael Amdahl; Mario Cozzolino; David Goldsmith; Amit Sharma; Steven Marx; Samina Khan Journal: Nephrol Dial Transplant Date: 2012-03-02 Impact factor: 5.992
Authors: Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino Journal: Clin J Am Soc Nephrol Date: 2015-07-29 Impact factor: 8.237